Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Business & Regulation Advanced Medicine, Business Practice, Supply Chain, Trends & Forecasts

We Need to Talk About Cell and Gene Therapy

sponsored by MilliporeSigma, Sartorius

In my editorial for our last cell and gene therapy supplement, I wrote that many in the industry wouldn't be preoccupied with full stockings in the weeks leading up to Christmas, “but rather full schedules – with many conferences to attend.” Oh how times have changed!

This year’s supplement features Kelly Page, Head of Global Cell Therapy Commercialization at Takeda, Sandy Macrae, CEO of Sangamo Therapeutics, and David Meek, CEO of FerGene, who discuss what excites them the most about the field. We also get the cell and gene story from the ISCT – the society that was there at the very beginning – and interview Vered Caplan, CEO of Orgenesis.

You can find out more about the supplement and download the PDF here.

For weekly updates on the cell and gene therapy industry, subscribe to the Cell & Gene Curator newsletter

Subscribe to The Medicine Maker Newsletters

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].

About the Author

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at.

From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine